Our first product, Neovaso, addresses inherent limitations of synthetic bypass grafts in small vessel disease. Our technology has been demonstrated in preclinical and clinical studies to provide a robust conduit for arterial blood flow while promoting new tissue formation.
A truly functional small-diameter synthetic vascular graft would address a highly significant clinical need. Permanent synthetic grafts do not heal normally so remain vulnerable, indefinitely, to events that will cause graft failure from thrombosis. Our technology is designed to allow tissue to develop within the graft structure and then to promote adaptation and normal healing by allowing that tissue to be environmentally conditioned. While this concept is not new, our unique structure and material properties are aimed to enable a response that has not been possible before now.
Our technology creates a highly porous polymer cylinder utilizing an electrospinning process that contains blood flow while tissue infiltrates into and surrounding the graft. Over time, the graft weakens, which allows the new tissue to be exposed to pulsatile pressure — favoring development of stronger, more functional tissues.
¹ Data on file. Manuscript in press ² Biomaterials 2008;29:3213-20 ³ Nature Biotechnology, 1999;17:979-83 ⁴ Tissue Eng, 2010 16:3149-57.